menu
    • menu
    [{"orgOrder":0,"company":"Provectus Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Rose Bengal Disodium","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Provectus Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Provectus Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Provectus Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Provectus Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Rose Bengal Disodium","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Provectus Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Provectus Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Provectus Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Provectus Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Rose Bengal Disodium","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moffitt Cancer Center \/ Provectus Biopharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Moffitt Cancer Center \/ Provectus Biopharmaceuticals"},{"orgOrder":0,"company":"Provectus Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Rose Bengal Disodium","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Provectus Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Provectus Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Provectus Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"VisiRose","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Financing","leadProduct":"Rose Bengal Disodium","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"VisiRose","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VisiRose \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"VisiRose \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Rose Bengal Disodium

    Menu

    Rose Bengal Disodium

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            VisiRose

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            VisiRose

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rose Bengal Disodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $3.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Provectus Announces Seed Financing for VisiRose, Eye Drug Spinoff Company

                            Details : The financing is intended to support the clinical development of VisiRose’s formulated Rose Bengal Disodium for the treatment of infectious keratitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 14, 2025

                            Lead Product(s) : Rose Bengal Disodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $3.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Provectus Biopharmaceuticals

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Provectus Biopharmaceuticals

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rose Bengal Disodium

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver

                            Details : Rose Bengal Disodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neuroendocrine Tumors.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 26, 2016

                            Lead Product(s) : Rose Bengal Disodium

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Provectus Biopharmaceuticals

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Provectus Biopharmaceuticals

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rose Bengal Disodium

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

                            Details : Rose Bengal Disodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Melanoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 23, 2015

                            Lead Product(s) : Rose Bengal Disodium

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Provectus Biopharmaceuticals

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Provectus Biopharmaceuticals

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rose Bengal Disodium

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10

                            Details : Rose Bengal Disodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Psoriasis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 22, 2014

                            Lead Product(s) : Rose Bengal Disodium

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Moffitt Cancer Center

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Moffitt Cancer Center

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rose Bengal Disodium

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Provectus Biopharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study

                            Details : Rose Bengal Disodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Melanoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 04, 2013

                            Lead Product(s) : Rose Bengal Disodium

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Provectus Biopharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth